NeuroMetrix reports Q3 revenue $587,314 vs $1.2M last year

The company said, “Over the past several quarters, the Company has strengthened its Board of Directors, terminated common stock sales under its ATM program, implemented a reduction-in-force, and phased-out its legacy ADVANCE(R) business. As a result, operating expenses and cash usage have been lowered by over $0.5M per quarter. The Company continues to build the Quell Fibromyalgia business via direct-to-physician marketing and sales to Veterans Health Administration facilities. “